Anti-Transferrin Receptor (TFR) Aptamer Synthesis and Modification Service

General cancer-targeting aptamers, which are currently used to deliver drugs to cells, have received considerable attention from scientists. It has been shown that anti-TfR aptamers can also be used to deliver anti-cancer drugs to cells. Anti-TfR aptamers are promising candidates for diagnostic and therapeutic purposes due to their known high affinity and selectivity for target recognition.

CD Bioparticles offers anti-TFR aptamer synthesis and modification services and provides a valuable reference for studying the role of aptamer-targeted TFR proteins in cancer drug delivery through aptamer synthesis and modification. We are able to exploit the unique advantages of aptamers in disease-targeted diagnosis and treatment.

Introduction to Anti-TfR Aptamers

Transferrin receptor I (TfR), also known as CD71, is a type II transmembrane glycoprotein that acts as a cell membrane receptor for human transferrin (HTf). HTFR continuously transports extracellular iron-loaded hTf (holo hTf) into the cell and is involved not only in iron homeostasis but also in a number of physiological processes related to cell growth.

TfR is upregulated in a variety of tumours and its expression correlates with tumour malignancy, such as metastasis and drug resistance. Due to its widespread expression in tumour cells and its efficient endocytosis, TfR has been widely used as a versatile tool to study the targeted delivery of disease-specific therapeutics. The most common ligands used to study TfR-mediated endocytosis or drug delivery are HTF or anti-TfR antibodies covalently coupled to chemical molecules or nanoparticles.

Fig. 1 CD71 receptor: ligand recognition epitopes and binding modes. CD71 residues identified as recognition epitopes for Tf/HFE and viruses/parasites are represented as orange/wheat and red/pink surfaces, respectively (Montemiglio LC, et al., 2019)

Our Anti-TFR Aptamer Services

CD Bioparticles is engaged in the synthesis and modification of anti-TfR aptamer. Our services utilize our highly innovative SELEX technology to rapidly develop aptamers that bind with high affinity to target molecules. Our team offers services from aptamer construction to the study of targeted drug delivery systems using modified aptamers. Our services focus on but are not limited to the following:

• Anti- TFR Aptamer Design

We will work with you to design aptamers specifically for the TfR receptor or any other target protein of interest.

• Anti- TFR Aptamer Synthesis

We offer custom anti-TfR aptamer synthesis services using a range of techniques including solid phase synthesis, enzymatic synthesis, and chemical synthesis.

• Anti- TFR Aptamer Modification

We can further modify anti-TfR aptamer to improve their binding affinity, stability, and specificity to the target protein. This includes chemical modifications, conjugation to different tags or fluorophores, and incorporation of anti-nuclease ligands.

• Characterisation of Anti- TFR Aptamer

A range of assays can be used to characterize the binding properties of anti-TfR aptamer, including surface plasmon resonance (SPR), fluorescence polarisation (FP), and gel shift assays.

• Anti- TFR Aptamer Specificity and Affinity Analysis

Flow cytometry and microscopy are used to assess the specificity and affinity of the target.

• Anti- TFR Aptamer Targeted Drug Delivery

In vitro and in vivo assays are used to demonstrate the ability of our aptamers to direct tissue-specific drug uptake.

• Anti- TFR Aptamer Optimisation

We offer optimization services to improve the properties of aptamers for your specific application. This includes optimization of the aptamer sequence, modification of the aptamer structure and optimization of the attachment chemistry.

CD Bioparticles offers services for the synthesis and modification of anti-TfR aptamers. We have developed a wide range of aptamers that bind to cell surface receptors, exploiting the unique advantages of nucleic acid aptamers for targeted disease diagnosis and treatment. If you are interested in our services, please do not hesitate to contact us.

Quotations and Ordering

References

1. Montemiglio, LC.; et al. Cryo-EM structure of the human ferritin-transferrin receptor 1 complex. Nat Commun. 2019; 10 (1): 1121.
2. Daniels, T.; et al. RThe transferrin receptor part I: biology and targeting with cytotoxic antibodies Clin. Immunol. 2006; 121: 144-158.
3. Daniels, TR.; et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochimica et Biophysica Acta. 2012; 1820: 291-317.